Systemic inflammation is associated with incident stroke and heart disease in East Asians.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
27 03 2020
Historique:
received: 01 09 2019
accepted: 12 03 2020
entrez: 30 3 2020
pubmed: 30 3 2020
medline: 30 3 2020
Statut: epublish

Résumé

Systemic inflammation, reflected by increased plasma concentrations of C-reactive protein (CRP) and fibrinogen, is associated with increased risk of coronary heart disease, but its relevance for stroke types remains unclear. Moreover, evidence is limited in non-European populations. We investigated associations of CRP and fibrinogen with risks of incident major coronary events (MCE), ischemic stroke (IS) and intracerebral hemorrhage (ICH) in a cohort of Chinese adults. A nested case-control study within the prospective China Kadoorie Biobank included 1,508 incident MCE cases, 5,418 IS cases, 4,476 ICH cases, and 5,285 common controls, aged 30-79 years. High-sensitivity CRP and low-density lipoprotein cholesterol (LDL-C) were measured in baseline plasma samples from all participants, and fibrinogen in a subset (n = 9,380). Logistic regression yielded adjusted odds ratios (ORs) per SD higher usual levels of log-transformed CRP and fibrinogen. The overall mean (SD) baseline LDL-C was 91.6 mg/dL (24.0) and geometric mean (95% CI) CRP and fibrinogen were 0.90 mg/L (0.87-0.93) and 3.01 g/L (2.98-3.03), respectively. There were approximately log-linear positive associations of CRP with each outcome, which persisted after adjustment for LDL-C and other risk factors, with adjusted ORs (95% CI) per SD higher CRP of 1.67 (1.44-1.94) for MCE and 1.22 (1.10-1.36) for both IS and ICH. No associations of fibrinogen with MCE, IS, or ICH were identified. Adding CRP to prediction models based on established risk factors improved model fit for each of MCE, IS, and ICH, with small improvements in C-statistic and correct reclassification of controls to lower risk groups. Among Chinese adults, who have low mean LDL-C, CRP, but not fibrinogen, was independently associated with increased risks of MCE and stroke.

Identifiants

pubmed: 32221345
doi: 10.1038/s41598-020-62391-3
pii: 10.1038/s41598-020-62391-3
pmc: PMC7101367
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5605

Subventions

Organisme : Cancer Research UK
ID : 29186
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12026/2
Pays : United Kingdom
Organisme : Wellcome Trust (Wellcome)
ID : 104085/Z/14/Z
Pays : International
Organisme : Medical Research Council
ID : MC_UU_00017/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U137686851
Pays : United Kingdom
Organisme : BHF Centre of Research Excellence, Oxford (BHF Centre of Research Excellence in Oxford)
ID : FS/18/23/33512
Pays : International
Organisme : Medical Research Council
ID : MC_PC_13049
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_14135
Pays : United Kingdom
Organisme : Wellcome Trust (Wellcome)
ID : 088158/Z/09/Z
Pays : International
Organisme : Medical Research Council
ID : MC_U137686855
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 212946/Z/18/Z
Pays : United Kingdom

Investigateurs

Rory Collins (R)
Depei Liu (D)
Richard Peto (R)
Ruth Boxall (R)
Yumei Chang (Y)
Yiping Chen (Y)
Simon Gilbert (S)
Alex Hacker (A)
Andri Iona (A)
Rene Kerosi (R)
Ling Kong (L)
Om Kurmi (O)
Garry Lancaster (G)
Sarah Lewington (S)
Kuang Lin (K)
John McDonnell (J)
Qunhua Nie (Q)
Paul Ryder (P)
Sam Sansome (S)
Paul Sherliker (P)
Rajani Sohoni (R)
Becky Stevens (B)
Jenny Wang (J)
Lin Wang (L)
Neil Wright (N)
Ling Yang (L)
Xiaoming Yang (X)
Pang Yao (P)
Xiao Han (X)
Can Hou (C)
Pei Pei (P)
Chao Liu (C)
Zengchang Pang (Z)
Ruqin Gao (R)
Shanpeng Li (S)
Shaojie Wang (S)
Yongmei Liu (Y)
Ranran Du (R)
Liang Cheng (L)
Xiaocao Tian (X)
Hua Zhang (H)
Yaoming Zhai (Y)
Feng Ning (F)
Xiaohui Sun (X)
Feifei Li (F)
Silu Lv (S)
Junzheng Wang (J)
Wei Hou (W)
Mingyuan Zou (M)
Shichun Yan (S)
Xue Zhou (X)
Bo Yu (B)
Yanjie Li (Y)
Qinai Xu (Q)
Quan Kang (Q)
Ziyan Guo (Z)
None Dan Wang
Ximin Hu (X)
Jinyan Chen (J)
Yan Fu (Y)
Xiaohuan Wang (X)
Min Weng (M)
Zhendong Guo (Z)
Shukuan Wu (S)
Yilei Li (Y)
Huimei Li (H)
Ming Wu (M)
Yonglin Zhou (Y)
Jinyi Zhou (J)
Ran Tao (R)
Jie Yang (J)
Jian Su (J)
Fang Liu (F)
Jun Zhang (J)
Yihe Hu (Y)
Yan Lu (Y)
Liangcai Ma (L)
Aiyu Tang (A)
Yujie Hua (Y)
Jianrong Jin (J)
Jingchao Liu (J)
Zhenzhu Tang (Z)
Naying Chen (N)
Ying Huang (Y)
Mingqiang Li (M)
Jinhuai Meng (J)
Rong Pan (R)
Qilian Jiang (Q)
Jian Lan (J)
Yun Liu (Y)
Liuping Wei (L)
Liyuan Zhou (L)
Ningyu Chen (N)
Ping Wang (P)
Fanwen Meng (F)
Yulu Qin Sisi Wang (YQS)
Xianping Wu (X)
Ningmei Zhang (N)
Xiaofang Chen (X)
Weiwei Zhou (W)
Guojin Luo (G)
Jianguo Li (J)
Xiaofang Chen (X)
Xunfu Zhong (X)
Jiaqiu Liu (J)
Qiang Sun (Q)
Pengfei Ge (P)
Xiaolan Ren (X)
Caixia Dong (C)
Hui Zhang (H)
Enke Mao (E)
Xiaoping Wang (X)
Tao Wang (T)
Xi Zhang (X)
Ding Zhang Zhou (DZ)
Gang Zhou (G)
Shixian Feng (S)
Ling Chang (L)
Lei Fan (L)
Yulian Gao (Y)
Tianyou He (T)
Huarong Sun (H)
Pan He (P)
Chen Hu (C)
Xukui Zhang (X)
Huifang Wu (H)
Min Yu (M)
Ruying Hu (R)
Hao Wang (H)
Weiwei Gong (W)
Meng Wang (M)
Kaixu Xie (K)
Lingli Chen (L)
Dongxia Pan (D)
Qijun Gu (Q)
Yuelong Huang (Y)
Biyun Chen (B)
Li Yin (L)
Huilin Liu (H)
Zhongxi Fu (Z)
Qiaohua Xu (Q)
Xin Xu (X)
Hao Zhang (H)
Huajun Long (H)
Libo Zhang (L)

Commentaires et corrections

Type : ErratumIn

Références

Roth, G. A. et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J. Am. Coll. Cardiol. 70, 1–25 (2017).
pubmed: 28527533 pmcid: 5491406 doi: 10.1016/j.jacc.2017.04.052
Stewart, J., Manmathan, G. & Wilkinson, P. Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. JRSM Cardiovasc. Dis. 6, 2048004016687211 (2017).
pubmed: 28286646 pmcid: 5331469
Ridker, P. M. Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. J. Am. Coll. Cardiol. https://doi.org/10.1016/j.jacc.2018.06.082 (2018).
Tousoulis, D., Charakida, M. & Stefanadis, C. Endothelial function and inflammation in coronary artery disease. Heart 92, 441–444 (2006).
pubmed: 16159981 pmcid: 16159981
Ruparelia, N., Chai, J. T., Fisher, E. A. & Choudhury, R. P. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat. Rev. Cardiol. 14, 133–144 (2017).
pubmed: 27905474 doi: 10.1038/nrcardio.2016.185 pmcid: 27905474
Swirski, F. K. & Nahrendorf, M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339, 161–166 (2013).
pubmed: 23307733 pmcid: 3891792 doi: 10.1126/science.1230719
Ramji, D. P. & Davies, T. S. Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor. Rev. 26, 673–685 (2015).
pubmed: 26005197 pmcid: 4671520 doi: 10.1016/j.cytogfr.2015.04.003
Willerson, J. T. & Ridker, P. M. Inflammation as a cardiovascular risk factor. Circulation 109, II2–10 (2004).
pubmed: 15173056 pmcid: 15173056
Ridker, P. M. et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med. 377, 1119–1131 (2017).
pubmed: 28845751 doi: 10.1056/NEJMoa1707914 pmcid: 28845751
Ridker, P. M. Targeting inflammatory pathways for the treatment of cardiovascular disease. Eur. Hear. J. 35, 540–543 (2014).
doi: 10.1093/eurheartj/eht398
Agrawal, A., Hammond, D. J. Jr. & Singh, S. K. Atherosclerosis-related functions of C-reactive protein. Cardiovasc. Hematol. Disord. Drug. Targets 10, 235–240 (2010).
pubmed: 20932269 pmcid: 3125067 doi: 10.2174/187152910793743841
Abd, T. T. et al. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial. Curr. Atheroscler. Rep. 13, 154–161 (2011).
pubmed: 21274757 doi: 10.1007/s11883-011-0164-5 pmcid: 21274757
Blake, G. J. & Ridker, P. M. C-reactive protein, subclinical atherosclerosis, risk cardiovascular events. Arter. Thromb. Vasc. Biol. 22, 1512–1513 (2002).
doi: 10.1161/01.ATV.0000038145.59548.85
Quaglia, L. A. et al. C-reactive protein is independently associated with coronary atherosclerosis burden among octogenarians. Aging Clin. Exp. Res. 26, 19–23 (2014).
pubmed: 23959959 doi: 10.1007/s40520-013-0114-x pmcid: 23959959
Zhang, Y. et al. Higher fibrinogen level is independently linked with the presence and severity of new-onset coronary atherosclerosis among Han Chinese population. PLoS One 9, e113460 (2014).
pubmed: 25426943 pmcid: 4245131 doi: 10.1371/journal.pone.0113460
Green, D., Foiles, N., Chan, C., Schreiner, P. J. & Liu, K. Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study. Atherosclerosis 202, 623–631 (2009).
pubmed: 18602107 doi: 10.1016/j.atherosclerosis.2008.05.039 pmcid: 18602107
Emerging Risk Factors Collaboration. et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375, 132–140 (2010).
doi: 10.1016/S0140-6736(10)60484-9
Fibrinogen Studies Collaboration. et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294, 1799–1809 (2005).
Liu, Y. et al. Relationship between C-reactive protein and stroke: a large prospective community based study. PLoS One 9, e107017 (2014).
pubmed: 25191699 pmcid: 4156395 doi: 10.1371/journal.pone.0107017
Saito, I., Maruyama, K. & Eguchi, E. C-reactive protein and cardiovascular disease in East asians: a systematic review. Clin. Med. Insights Cardiol. 8, 35–42 (2014).
pubmed: 25698882 pmcid: 25698882
Wakugawa, Y. et al. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama Study. Stroke 37, 27–32 (2006).
pubmed: 16306468 doi: 10.1161/01.STR.0000194958.88216.87 pmcid: 16306468
C. Reactive Protein Coronary Heart Disease Genetics Collaboration. et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 342, d548 (2011).
doi: 10.1136/bmj.d548
Elliott, P. et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302, 37–48 (2009).
pubmed: 19567438 pmcid: 2803020 doi: 10.1001/jama.2009.954
Zacho, J. et al. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 359, 1897–1908 (2008).
pubmed: 18971492 doi: 10.1056/NEJMoa0707402 pmcid: 18971492
Keavney, B. et al. Fibrinogen and coronary heart disease: test of causality by ‘Mendelian randomization’. Int. J. Epidemiol. 35, 935–943 (2006).
pubmed: 16870675 doi: 10.1093/ije/dyl114 pmcid: 16870675
Sabater-Lleal, M. et al. Multiethnic meta-analysis of genome-wide association studies in > 100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease. Circulation 128, 1310–1324 (2013).
pubmed: 23969696 doi: 10.1161/CIRCULATIONAHA.113.002251 pmcid: 23969696
Ridker, P. M. et al. Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen. Circulation 126, 2739–2748 (2012).
pubmed: 23129601 doi: 10.1161/CIRCULATIONAHA.112.122556 pmcid: 23129601
Wang, W. et al. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. Circulation 135, 759–771 (2017).
pubmed: 28052979 doi: 10.1161/CIRCULATIONAHA.116.025250 pmcid: 28052979
Chen, Z. et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int. J. Epidemiol. 40, 1652–1666 (2011).
pubmed: 22158673 pmcid: 3235021 doi: 10.1093/ije/dyr120
Vickers, A. J., Cronin, A. M. & Begg, C. B. One statistical test is sufficient for assessing new predictive markers. BMC Med. Res. Methodol. 11, 13 (2011).
pubmed: 21276237 pmcid: 3042425 doi: 10.1186/1471-2288-11-13
Danesh, J. et al. C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease. N. Engl. J. Med. 350, 1387–1397 (2004).
pubmed: 15070788 doi: 10.1056/NEJMoa032804 pmcid: 15070788
Bos, M. J. et al. High serum C-reactive protein level is not an independent predictor for stroke: The Rotterdam Study. Circulation 114, 1591–1598 (2006).
pubmed: 17015791 doi: 10.1161/CIRCULATIONAHA.106.619833 pmcid: 17015791
Tsai, C. F., Anderson, N., Thomas, B. & Sudlow, C. L. Comparing Risk Factor Profiles between Intracerebral Hemorrhage and Ischemic Stroke in Chinese and White Populations: Systematic Review and Meta-Analysis. PLoS One 11, e0151743 (2016).
pubmed: 26991497 pmcid: 4798495 doi: 10.1371/journal.pone.0151743
Wang, X., Dong, Y., Qi, X., Huang, C. & Hou, L. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke 44, 1833–1839 (2013).
pubmed: 23704101 doi: 10.1161/STROKEAHA.113.001326 pmcid: 23704101
Chen, Z. et al. Adiposity and risk of ischaemic and haemorrhagic stroke in 0.5 million Chinese men and women: a prospective cohort study. Lancet Glob. Heal. 6, e630–e640 (2018).
doi: 10.1016/S2214-109X(18)30216-X
Gruppen, E. G. et al. GlycA, a Pro-Inflammatory Glycoprotein Biomarker, and Incident Cardiovascular Disease: Relationship with C-Reactive Protein and Renal Function. PLoS One 10, e0139057 (2015).
pubmed: 26398105 pmcid: 4580603 doi: 10.1371/journal.pone.0139057
Holmes, M. V. et al. Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. J. Am. Coll. Cardiol. 71, 620–632 (2018).
pubmed: 29420958 pmcid: 5811927 doi: 10.1016/j.jacc.2017.12.006
Everett, B. M. et al. Rationale and design of the Cardiovascular Inflammation Reduction. Trial: a test. Inflamm. hypothesis atherothrombosis. Am. Hear. J. 166, 199–207 e15 (2013).
Ridker, P. M. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ. Res. 118, 145–156 (2016).
pubmed: 26837745 pmcid: 4793711 doi: 10.1161/CIRCRESAHA.115.306656
Lacey, B. et al. Age-specific association between blood pressure and vascular and non-vascular chronic diseases in 0.5 million adults in China: a prospective cohort study. Lancet Glob. Heal. 6, e641–e649 (2018).
doi: 10.1016/S2214-109X(18)30217-1
IL6R. Genetics Consortium Emerging Risk Factors Collaboration et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379, 1205–1213 (2012).
doi: 10.1016/S0140-6736(11)61931-4
Interleukin-6 Receptor Mendelian Randomisation Analysis Consortium. et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379, 1214–1224 (2012).
doi: 10.1016/S0140-6736(12)60110-X
Chen, Z. et al. Cohort profile: the Kadoorie Study of Chronic Disease in China (KSCDC). Int. J. Epidemiol. 34, 1243–1249 (2005).
pubmed: 16131516 doi: 10.1093/ije/dyi174 pmcid: 16131516
Lenth, R. V. Least-Squares Means: R. Package lsmeans. 2016(69), 33 (2016).
Viechtbauer, W. Conducting Meta-Analyses R. Metaf. Package. 2010(36), 48 (2010).
Bragg, F. et al. Association of Random Plasma Glucose Levels With the Risk for Cardiovascular Disease Among Chinese Adults Without Known Diabetes. JAMA Cardiol. 1, 813–823 (2016).
pubmed: 27437922 doi: 10.1001/jamacardio.2016.1702 pmcid: 27437922
Bennett, D. A. et al. Association of Physical Activity With Risk of Major Cardiovascular Diseases in Chinese Men and Women. JAMA Cardiol. 2, 1349–1358 (2017).
pubmed: 29117341 pmcid: 5814992 doi: 10.1001/jamacardio.2017.4069
Millwood, I. Y. et al. Alcohol consumption in 0.5 million people from 10 diverse regions of China: prevalence, patterns and socio-demographic and health-related correlates. Int. J. Epidemiol. 42, 816–827 (2013).
pubmed: 23918852 pmcid: 3733702 doi: 10.1093/ije/dyt078
Plummer, M. Improved estimates of floating absolute risk. Stat. Med. 23, 93–104 (2004).
pubmed: 14695642 doi: 10.1002/sim.1485 pmcid: 14695642
Rosner, B., Willett, W. C. & Spiegelman, D. Correction of logistic regression relative risk estimates and confidence intervals for systematic within-person measurement error. Stat. Med. 8, 1051–1053 (1989).
pubmed: 2799131 doi: 10.1002/sim.4780080905 pmcid: 2799131

Auteurs

Mohd A Karim (MA)

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Christiana Kartsonaki (C)

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Derrick A Bennett (DA)

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Iona Y Millwood (IY)

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Michael R Hill (MR)

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Daniel Avery (D)

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Zheng Bian (Z)

Chinese Academy of Medical Sciences, Beijing, China.

Huaidong Du (H)

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Yu Guo (Y)

Chinese Academy of Medical Sciences, Beijing, China.

Yijian Qian (Y)

Tongxiang Centre for Disease Control and Prevention, Tongxiang, Zhejiang Province, China.

Chan Qu (C)

NCDs Prevention and Control Department, Liuyang Centre for Disease Control and Prevention, Liuyang, Hunan Province, China.

Iain Turnbull (I)

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Dan Schmidt-Valle (D)

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Chunmei Wang (C)

Tongxiang Centre for Disease Control and Prevention, Tongxiang, Zhejiang Province, China.

Canqing Yu (C)

Chinese Academy of Medical Sciences, Beijing, China.

Jun Lv (J)

Department of Epidemiology, School of Public Health, Peking University Health Science Center, Beijing, China.

Junshi Chen (J)

China National Center for Food Safety Risk Assessment, Beijing, China.

Robert Clarke (R)

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Liming Li (L)

Department of Epidemiology, School of Public Health, Peking University Health Science Center, Beijing, China.

Zhengming Chen (Z)

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Michael V Holmes (MV)

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. michael.holmes@ndph.ox.ac.uk.
Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. michael.holmes@ndph.ox.ac.uk.
National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospital, Oxford, United Kingdom. michael.holmes@ndph.ox.ac.uk.

Robin G Walters (RG)

Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. robin.walters@ndph.ox.ac.uk.
Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. robin.walters@ndph.ox.ac.uk.

Classifications MeSH